Trial Search Results

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

This clinical study will evaluate whether taking an investigational drug called exendin 9-39 is safe, well-tolerated, and helps to prevent low blood sugar in people who have had bariatric surgery and later develop a rare condition called postbariatric hypoglycemia (PBH).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Eiger BioPharmaceuticals

Stanford Investigator(s):


  • Drug: exendin 9-39
  • Other: Placebo


Phase 2


Inclusion Criteria:

   - Body mass index (BMI) of up to 40 kg/m2

   - Roux-en-Y gastric bypass (RYGB) surgery performed ≥12 months prior

   - Diagnosis of PBH

   - At least 2 episodes during screening 2-week run-in phase of severe hypoglycemia

Exclusion Criteria:

   - Other cause of endogenous hyperinsulinism other than PBH

   - Metabolic or bariatric surgical procedure other than RYGB

   - History of non-RYGB upper GI surgery

   - Use of agents that may interfere with glucose metabolism

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Aileen Muno
(650) 725-9890
Not Recruiting